E1	Condition:T1 Name:T2 Stage:E3
E5	Condition:T5 Name:T6
E7	Condition:T7 Name:T8
E9	Condition:T9 Name:T10 Temporality:E28
E11	Condition:T11 Name:T12
E13	Condition:T13 Name:T14
E15	Condition:T15 Name:T16
E16	Age:T22 Eq-Comparison:E18
E17	Eq-Comparison:T27 Operator:T17 Value:T26 Per:T40
E18	Eq-Comparison:T28 Operator:T23 Value:T24 Value2:T25
E2	Or:T29 Arg:T4 Arg2:T3
E3	Eq-Comparison:T30 Value:T31
E4	Condition:T32 Name:T33 Stage:E6
E6	Eq-Comparison:T34 Value:T35
E8	Condition:T36 Name:T37
E10	Observation:T38 Name:T39 Eq-Comparison:E17
E12	Observation:T41 Name:T42 Eq-Comparison:E14
E14	Eq-Comparison:T43 Operator:T18 Value:T44
E19	Condition:T45
E20	Modifier:T46 Modifies:E19
E21	Condition:T47 Name:T48
E22	Exception:T49 From:E19 Except:E21
E23	Drug:T50 Name:T51 Temporality:E25
E24	Study:T52
E25	Eq-Comparison:T53 Operator:T19 Temporal-Unit:T55 Value:T54
E26	Temporal-Connection:T56 Arg:E25 Arg2:E24
E27	Or:T57 Arg:E9 Arg2:E13
E28	Eq-Comparison:T58 Temporal-Period:T59
E29	Condition:T60
E30	Condition:T61 Name:T62 Stability:T64
E31	Risk:T63 Risk-For:E30
E32	Assertion:T65 Asserted:T64
E33	Drug:T66 Name:T67
E34	Condition:T68 Name:T69
E35	Drug:T70 Name:T71 Temporality:E39
E36	Drug:T72 Name:T73 Temporality:E37
E37	Eq-Comparison:T74 Temporal-Recency:T75
E38	Or:T76 Arg:E36 Arg2:E35
E39	Eq-Comparison:T77 Temporal-Unit:T21 Operator:T20 Value:T78
E40	Study:T79
E41	Temporal-Connection:T80 Arg:E39 Arg2:E40
E42	Eq-Comparison:T81 Temporal-Period:T82
E43	Condition:T83 Name:T84 Severity:T86
E44	Modifier:T85
E45	Condition:T87 Name:T88
E46	Modifier:T89 Modifies:T88
E47	Negation:T90 Negates:E45
E48	Assertion:T91 Asserted:E47
E49	Procedure:T92 Temporality:E42
E50	Condition:T93 Name:T94 Temporality:E51
E51	Eq-Comparison:T95 Temporal-Period:T96
T1	Condition 66 113	International Classification Headache Disorders
T2	Condition-Name 66 113	International Classification Headache Disorders
T3	Life-Stage-And-Gender 33 39	female
T4	Life-Stage-And-Gender 25 29	male
T5	Condition 769 798	amyotrophic lateral sclerosis
T6	Condition-Name 769 798	amyotrophic lateral sclerosis
T7	Condition 735 752	myasthenia gravis
T8	Condition-Name 735 752	myasthenia gravis
T9	Condition 603 618	substance abuse
T10	Condition-Name 603 618	substance abuse
T11	Condition 502 516	breast feeding
T12	Condition-Name 502 516	breast feeding
T13	Condition 619 629	dependence
T14	Condition-Name 619 629	dependence
T15	Condition 491 500	pregnancy
T16	Condition-Name 491 500	pregnancy
T17	Eq-Operator 191 203	greater than
T18	Eq-Operator 297 309	greater than
T19	Eq-Operator 560 566	within
T20	Eq-Operator 903 909	within
T21	Eq-Temporal-Unit 916 922	months
T22	Age 45 48	age
T23	Eq-Operator 51 52	-
T24	Eq-Value 49 51	18
T25	Eq-Value 52 54	65
T26	Eq-Value 204 205	4
T27	Eq-Comparison 191 208	greater than 4/10
T28	Eq-Comparison 49 52	18-
T29	Or 30 32	or
T30	Eq-Comparison 114 116	II
T31	Eq-Value 114 116	II
T32	Condition 118 122	ICHD
T33	Condition-Name 118 122	ICHD
T34	Eq-Comparison 123 125	II
T35	Eq-Value 123 125	II
T36	Condition 140 163	post-traumatic headache
T37	Condition-Name 140 163	post-traumatic headache
T38	Observation 177 187	pain score
T39	Observation-Name 177 187	pain score
T40	Eq-Unit 206 208	10
T41	Observation 257 296	Rancho Los Amigos cognitive scale score
T42	Observation-Name 257 296	Rancho Los Amigos cognitive scale score
T43	Eq-Comparison 297 315	greater than seven
T44	Eq-Value 310 315	seven
T45	Condition 355 372	medical condition
T46	Modifier 342 354	Uncontrolled
T47	Condition 384 387	PTH
T48	Condition-Name 384 387	PTH
T49	Exception 373 383	other than
T50	Drug 544 559	botulinum toxin
T51	Drug-Name 544 559	botulinum toxin
T52	Study 579 589	enrollment
T53	Eq-Comparison 560 575	within one year
T54	Eq-Value 567 570	one
T55	Eq-Temporal-Unit 571 575	year
T56	Temporal-Connection 576 578	of
T57	Or 618 619	/
T58	Eq-Comparison 595 602	current
T59	Eq-Temporal-Period 595 602	current
T60	Condition 635 652	medical condition
T61	Condition 681 712	neuromuscular junction blockade
T62	Condition-Name 681 712	neuromuscular junction blockade
T63	Risk 673 677	risk
T64	Stability 664 672	increase
T65	Assertion 658 663	would
T66	Drug 718 733	botulinum toxin
T67	Drug-Name 718 733	botulinum toxin
T68	Condition 754 767	Eaton Lambert
T69	Condition-Name 754 767	Eaton Lambert
T70	Drug 879 902	anti-seizure medication
T71	Drug-Name 879 902	anti-seizure medication
T72	Drug 860 875	anti-depressant
T73	Drug-Name 860 875	anti-depressant
T74	Eq-Comparison 856 859	new
T76	Or 876 878	or
T77	Eq-Comparison 903 922	within three months
T78	Eq-Value 910 915	three
T79	Study 939 944	study
T80	Temporal-Connection 923 925	of
T81	Eq-Comparison 523 528	prior
T82	Eq-Temporal-Period 523 528	prior
T83	Condition 419 423	pain
T84	Condition-Name 419 423	pain
T85	Modifier 411 418	chronic
T86	Severity 393 399	Severe
T87	Condition 481 485	pain
T88	Condition-Name 481 485	pain
T89	Modifier 472 480	headache
T90	Negation 446 449	not
T91	Assertion 440 445	could
T92	Procedure 529 538	treatment
T75	Eq-Temporal-Recency 856 859	new
T93	Condition 958 968	disability
T94	Condition-Name 958 968	disability
T95	Eq-Comparison 950 957	ongoing
T96	Eq-Temporal-Period 950 957	ongoing
A1	Life-Stage-And-Gender-Type T3 female
A2	Life-Stage-And-Gender-Type T4 male
A3	Eq-Operator-Value T17 GT
A4	Eq-Operator-Value T18 GT
A5	Eq-Operator-Value T19 LTEQ
A6	Eq-Operator-Value T20 LTEQ
A7	Eq-Temporal-Unit-Value T21 month
A8	Eq-Operator-Value T23 BETWEEN
A9	Observation-Type-Value T42 clinical-score
A10	Eq-Temporal-Unit-Value T55 year
A11	Temporal-Connection-Type-Value E26 before
A12	Eq-Temporal-Period-Value T59 present
A13	Stability-Value T64 change
A14	Assertion-Type-Value E32 hypothetical
A16	Temporal-Connection-Type-Value E41 after
A17	Eq-Temporal-Period-Value T82 past
A18	Severity-Value T86 severe
A19	Assertion-Type-Value E48 hypothetical
A15	Eq-Temporal-Recency-Value T75 first-time
A20	Eq-Temporal-Period-Value T96 present
R1	Abbrev-Of Arg1:E4 Arg2:E1
R2	Equivalent-To Arg1:E8 Arg2:E4
R3	Caused-By Arg1:E31 Arg2:E29
R4	Using Arg1:E30 Arg2:E33
R5	Example-Of Arg1:E7 Arg2:E29
R6	Example-Of Arg1:E34 Arg2:E29
R7	Example-Of Arg1:E5 Arg2:E29
R8	Abbrev-Of Arg1:E44 Arg2:E43
R9	Using Arg1:E49 Arg2:E23